pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rinvoq · news · pharmadog
← back to Rinvoq
News mentioning Rinvoq
18
stories
14d
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
biospace
14d
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
fiercebiotech
19d
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
biospace
Oct 19, 26
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
biospace
Oct 19, 26
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
fiercebiotech
Oct 12, 26
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 17, 26
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
Sep 17, 26
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
Sep 8, 26
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 28, 26
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 1, 26
Abivax shares surge as worries subside over immune drug’s cancer risk
biopharma dive
Jun 2, 26
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
biopharma dive